Nurix’s lead candidate bexobrutideg demonstrated an 83% objective response rate in relapsed/refractory CLL patients with a median of four prior lines of therapy, including two complete responses (4.3%). Responses deepened over time, yielding a median progression-free survival of 22.1 months, which compares favorably to existing BTK inhibitors. The Phase 1b dataset also showed no dose-limiting toxicities across tested dose levels, underscoring a strong tolerability profile for this BTK degrader.

As of year-end 2025, Nurix held cash, cash equivalents and marketable securities exceeding $650 million, providing runway into late 2028. This liquidity underpins the company’s commitment to aggressive clinical development—covering pivotal studies in oncology and IND-enabling work in autoimmune and inflammatory disease—and shields equity holders from near-term dilution.

In 2026, Nurix plans to complete enrollment in its DAYBreak CLL-201 Phase 2 study evaluating bexobrutideg 600 mg once daily in triple-exposed CLL/SLL patients and initiate the confirmatory DAYBreak CLL-306 Phase 3 trial. Concurrently, the company aims to submit an IND for a tablet formulation of bexobrutideg in autoimmune indications and advance its DEL-AI platform to nominate at least two additional degrader candidates for development.

Nurix’s collaboration with Gilead on an IRAK4 degrader (GS-6791) is in Phase 1 testing in healthy volunteers, with data readouts expected mid-2026 to inform co-development decisions. A STAT6 degrader program with Sanofi is progressing through lead optimization. These partnerships leverage Nurix’s targeted protein degradation expertise to diversify value drivers beyond oncology and position the company at the forefront of degrader-based therapies in immunology.